Since inflammation and coagulation are crosslinked with liver fibrosis and given the principal roles of TLR4 and PAR1 in inflammation and coagulation, respectively, we hypothesized that TLR4-TF-PAR1 axis would be a novel pathway involved in the pathogenesis of liver fibrosis and targeting that pathway could underlie the therapeutic benefits of TFAS. This evidence concerns the gene TLR4 and Hepatic fibrosis.